TY - JOUR
T1 - Effects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity
AU - Jiang, Man
AU - Wei, Qingqing
AU - Pabla, Navjotsin
AU - Dong, Guie
AU - Wang, Cong Yi
AU - Yang, Tianxin
AU - Smith, Sylvia B.
AU - Dong, Zheng
N1 - Funding Information:
We thank Dr. U. Hopfer at Case Western Reserve University for the rat kidney proximal tubular cell (RPTC) line. We also thank Dr. J. Yu at University of Pittsburgh for the rabbit polyclonal anti-PUMA antibody. The study was supported in part by grants from National Institutes of Health and Department of Veterans Affairs of USA.
PY - 2007/5/1
Y1 - 2007/5/1
N2 - Nephrotoxicity is a major side effect of cisplatin, a widely used cancer therapy drug. Recent work has suggested a role of p53 in renal cell injury by cisplatin. However, the mechanism of p53 activation by cisplatin is unclear. This study determined the possible involvement of oxidative stress in p53 activation under the pathological condition using in vitro and in vivo models. In cultured renal proximal tubular cells, cisplatin at 20 μM induced an early p53 phosphorylation followed by protein accumulation. Cisplatin also induced reactive oxygen species (ROS), among which hydroxyl radicals showed a rapid and drastic accumulation. Dimethylthiourea (DMTU) and N-acetyl-cysteine (NAC) attenuated hydroxyl radical accumulation, and importantly, diminished p53 activation during cisplatin treatment. This was accompanied by the suppression of PUMA-α, a p53-regulated apoptotic gene. Concomitantly, mitochondrial cytochrome c release and apoptosis were ameliorated. Notably, DMTU and NAC, when added post-cisplatin treatment, were also inhibitory to p53 activation and apoptosis. In C57BL/6 mice, cisplatin at 30 mg/kg induced p53 phosphorylation and protein accumulation, which was also abrogated by DMTU. DMTU also ameliorated tissue damage, tubular cell apoptosis and cisplatin-induced renal failure. Collectively, this study has suggested a role of oxidative stress, particularly hydroxyl radicals, in cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity.
AB - Nephrotoxicity is a major side effect of cisplatin, a widely used cancer therapy drug. Recent work has suggested a role of p53 in renal cell injury by cisplatin. However, the mechanism of p53 activation by cisplatin is unclear. This study determined the possible involvement of oxidative stress in p53 activation under the pathological condition using in vitro and in vivo models. In cultured renal proximal tubular cells, cisplatin at 20 μM induced an early p53 phosphorylation followed by protein accumulation. Cisplatin also induced reactive oxygen species (ROS), among which hydroxyl radicals showed a rapid and drastic accumulation. Dimethylthiourea (DMTU) and N-acetyl-cysteine (NAC) attenuated hydroxyl radical accumulation, and importantly, diminished p53 activation during cisplatin treatment. This was accompanied by the suppression of PUMA-α, a p53-regulated apoptotic gene. Concomitantly, mitochondrial cytochrome c release and apoptosis were ameliorated. Notably, DMTU and NAC, when added post-cisplatin treatment, were also inhibitory to p53 activation and apoptosis. In C57BL/6 mice, cisplatin at 30 mg/kg induced p53 phosphorylation and protein accumulation, which was also abrogated by DMTU. DMTU also ameliorated tissue damage, tubular cell apoptosis and cisplatin-induced renal failure. Collectively, this study has suggested a role of oxidative stress, particularly hydroxyl radicals, in cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity.
KW - Apoptosis
KW - Cisplatin
KW - Hydroxyl radical
KW - Nephrotoxicity
KW - Oxidative stress
KW - p53
UR - http://www.scopus.com/inward/record.url?scp=33947390474&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33947390474&partnerID=8YFLogxK
U2 - 10.1016/j.bcp.2007.01.010
DO - 10.1016/j.bcp.2007.01.010
M3 - Article
C2 - 17291459
AN - SCOPUS:33947390474
SN - 0006-2952
VL - 73
SP - 1499
EP - 1510
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
IS - 9
ER -